Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2008-07-01
2008-07-01
Sitton, Jehanne S (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C435S091200, C536S023100, C536S024300
Reexamination Certificate
active
10089595
ABSTRACT:
Provided are compositions, methods and uses for identifying persons at an increased risk of infection by, transmission of, or accelerated progression of a disease caused by an HIV-1 virus. Diagnostic, prognostic and combined therapeutic kits are also provided.
REFERENCES:
patent: 6372435 (2002-04-01), Kaslow et al.
patent: WO 98/05798 (1988-02-01), None
patent: WO 99/09162 (1999-02-01), None
patent: WO 99/23253 (1999-05-01), None
patent: WO 01/12857 (2001-02-01), None
patent: WO 01/77125 (2001-04-01), None
Mummidi et al; Nature Medicine, vol. 4, Jul. 1998, pp. 786-793.
Buseyne et al; Journal of Infectious Diseases, Oct. 1998, vol. 178, pp. 1019-1023.
Hogg et al; The Lancet, vol. 349, p. 1294, 1997.
Gonzalez et al; PNAS, vol. 96, pp. 12004-12009; Oct. 12, 1999.
Szalai et al; Pediatric Research, Jul. 1999; vol. 46, 82-84.
Daly et al., “High-Resolution Haplotype Structure in the Human Genome,”Nature Genetics, 29:229-232, 2001.
Dean et al., “Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of theCKR5Structure Gene,”Science, 273:1856-1862, 1996.
Garred et al., “CC Chemokine Receptor 5 Polymorphism in Rheumatoid Arthritis,”J. Rheumatol., 25(8):1462-1465, 1998.
Gomez-Reino et al., “Association of Rheumatoid Arthritis with a Functional Chemokine Receptor, CCR5,”Arthritis&Rheumatism, 42(5):989992, 1999.
Gonzalez et al., “Global Survey of Genetic Variation inCCR5, RANTES,andMIP-1α: Impact on the Epidemiology of the HIV-1 Pandemic,”PNAS, 98(9):5199-5204, 2001.
Gonzalez et al., “Race-Specific HIV-1 Disease-Modifying Effects associated withCCR5Haplotypes,”PNAS, 96(21):12004-12009, 1999.
Hall et al., “Association of CCR5 Δ32 with Reduced Risk of Asthma,”The Lancet, 354:1264-1265, 1999.
Helms, “CCR5-Δ32 Polymorphism in Asthma,”The Lancet, 357:802, 2001.
Jiang et al., “Chemokine Receptor Expression in Cultured Glia and Rat Experimental Allergic Encephalomyelitis,”J. Neuroimmunol., 86:1-12, 1998.
Johnson et al., “Haplotype Tagging for the Identification of Common Disease Genes,”Nature Genetics, 29:233-237, 2001.
Karpas et al., “Are Anti-HIV Drugs an Effective Treatment,”Nature Medicine, 3(10):1052-1053, 1997.
Kostrikis et al., “A Polymorphism in the Regulatory Region of the CC-Chemokine Receptor 5 Gene Influences Perinatal Transmission of Human Immunodeficiency Virus Type 1 to African-American Infants,”J. Virol., 73(12):10264-10271, 1999.
Liu et al., “Homozygous Defect in HIV-1 Co receptor Accounts for Resistance of Some Multiple-Exposed Individuals to HIV-1 Infection,”Cell, 86:367-377, 1996.
Mangano et al., “Concordance Between the CC Chemokine Receptor 5 Genetic Determinants that Alter Risks of Transmission and Disease Progression in Children Exposed Perinatally to Human Immunodeficiency Virus,”J. Infect. Disease, 183:1574-1585, 2001.
Martin et al., Genetic Acceleration of AIDS Progression by a Promoter Variant ofCCR5, Science, 282:1907-1911, 1998.
McDermott et al., “CCR5 Promoter Polymorphism and HIV-1 Disease Progression,”The Lancet, 352:866-870, 1998.
Mummidi et al., “Evolution of Human and Non-Human Primate CC Chemokine Receptor 5 Gene and mRNA,”J. Biol. Chem., 275(25):18946-18961, 2000.
Mummidi et al., “Genealogy of theCCR5Locus and Chemokine System Gene Variants Associate with Altered Rates of HIV-1 Disease Progression,”Nature Medicine, 4(7):786-793, 1998.
Mummidi et al., “The Human CC Chemokine Receptor 5 (CCR5) Gene,”J. Biol. Chem., 272(49):30662-30671, 1997.
Nguyen et al., “Phenotypic Expressions ofCCR5-Δ32/ Δ32Homozygosity,”JAIDS, 22:75-82, 1999.
Sabbe et al., “Donor- and Ligand-Dependent Differences in C-C Chemokine Receptor 5 Reexpression,”J. Virol., 75(2):661-671, 2001.
Samson et al., “Resistance to HIV-1 Infection in Caucasian Individuals Bearing Mutant Alleles of the CCR-5 Chemokine Receptor Gene,”Nature, 382:722-725, 1996.
Segerer et al., “Expression of Chemokines and Chemokine Receptors During Human Renal Transplant Rejection,”Am. J. Kidney Diseases, 37(3):518-531, 2001.
Tang et al., “Allelic Variants of Human Beta-Chemokine Receptor 5 (CCR5) Promoter: Evolutionary Relationships and Predictable Associations withHIV-1 Disease Progression,”Genes and Immunity., 1:20-27, 1999.
Tran et al., “Induction of Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice Deficient in Either the Chemokine Macrophage Inflammatory Protein-1α or its CCR5 Receptor,”Eur. J. Immunol., 30:1410-1415, 2000.
International Search Report for PCT Application Serial No. PCT/US00/28158, Jun. 28, 2001.
Anzala et al. CCR2-64I allele and genotype association with delayed AIDS progression in African womenThe Lancet351:1632-1633 (1998).
Biti et al. “HIV-1 infection in an individual homozygous for theCCR5deletion allele”Nature Medicine3(3):252-253 (1997).
Dean et al. “Genetic Restriction of HIV-1 Infection and Progression to AIDS by Deletion Allele of theCKR5Structural Gene”Science273:1856-1862 (1996).
Esposito et al. “Role ofCCR5Chemokine Receptor Gene in Vertical Human Immunodeficiency Virus Type 1 Transmission and Disease Progression”The Pediatric Infectious Disease Journal17(9):847-849 (1998).
Eugen-Olsen et al. “Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals”AIDS11:305-310 (1997).
Eugen-Olsen et al. “Chemokine Receptor CCR2b 64I Polymorphism and its Relation to CD4 T-Cell Counts and Disease Progression in a Danish Cohort of HIV-Infected Individuals”J. Acquir. Immune Def. Syndr. Hum. Retrovirol. 18:110-116 (1998).
Garred et al. “Dual effect of CCR5 Δ32 gene deletion in HIV-1-infected patients”The Lancet349:1884 (1997).
Garred et al. “Chemokine-receptor polymorphisms: clarity or confusion for HIV-1 prognosis?”The Lancet351:2-3 (1998).
Hendel et al. “Distinctive Effects ofCCR5, CCR2 and SDF1Genetic Polymorphisms in AIDS Progression”J. Acquir. Immune Def. Syndr. Hum. Retrovirol. 19:381-386 (1998).
Huang et al. “The role of a mutant CCR5 allele in HIV-1 transmission and disease progression”Nature Medicine2(11):1240-1243 (1996).
Husman et al. “Association between CCR5 Genotype and the Clinical Course of HIV-1 Infection”Annals of Internal Medicine127(10):882-890 (1997).
Ioannidis et al. “Genetic effects on HIV disease progression”Nature Medicine4(5):536 (1998).
Just et al. “Influence of host genotype on progression to acquired immunodeficiency syndrome among children infected with human immunodeficiency virus type 1”The Journal of Pediatrics127(4):544-549 (1995).
Katzenstein et al. “HIV-Infected Individuals With the CCR Δ32/CCR5 Genotype Have Lower HIV RNA Levels and Higher CD4 Cell Counts in the Early Years of the Infection Than Do Patients With the Wild Type”J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 16:10-14 (1997).
Kostrikis et al. “A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation”Nature Medicine4(3):350-353 (1998).
Libert et al. “TheΔccr5mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe”Human Molecular Genetics7(3):399-406 (1998).
Lucotte, G. “Frequencies of the CC chemokine receptor 5 Δ32 allele in various populations of defined racial background”Biomed&Pharmacother51:469-473 (1997).
Mandl et al. “Possible influence of the Mutant CCR5 Allele on Vertical Transmission of HIV-1”Journal of Medical Virology55:51-55 (1998).
Mangano et al. “Distribution ofCCR-5 Δ32allele in Argenti
Ahuja Sunil
Bamshad Mike
Dolan Matthew J.
Gonzales Enrique
Mummidi Srinivas
Myers Bigel Sibley & Sajovec P.A.
Sitton Jehanne S
The University of Texas System & Board of Regents
The University of Utah Research Foundation
United States of America as represented by the Secretary of the
LandOfFree
Screening for disease susceptibility by genotyping the CCR5... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Screening for disease susceptibility by genotyping the CCR5..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Screening for disease susceptibility by genotyping the CCR5... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3944739